AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22113068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of 100 g of blanched Agaricus bisporus white button mushroom daily for 1 week
Number of subjects: 24
Study 22113068 — intervention group
Group type: COMPARATOR
Intervention: Normal daily diet without WBM (control group)
Number of subjects: 24
Study 22113068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of 100 g of blanched Agaricus bisporus white button mushroom
Number of subjects: 24
Study 19945492 — intervention group
Group type: EXPERIMENTAL
Intervention: Chickpea supplemented diet (average 104 g/day)
Number of subjects: 42
Study 19945492 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 42
Study 17494881 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and steroids (prednisolone) for 6 months
Number of subjects: 93
Study 17494881 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatment (control group)
Number of subjects: 93
Study 16327614 — intervention group
Group type: COMPARATOR
Intervention: Preoperative single intravenous dose of antibiotics
Number of subjects: 200
Study 16327614 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regimen with preoperative single-shot antibiotics plus a postoperative 7-day course of oral antibiotics
Number of subjects: 200
Study 11872885 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based heparin nomogram
Number of subjects: 206
Study 11453902 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1%
Number of subjects: 6
Study 11453902 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin 0.025%
Number of subjects: 6
Study 11453902 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 1%
Number of subjects: 6
Study 11453902 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 1% + Tretinoin 0.025%
Number of subjects: 6
Study 11453902 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5%
Number of subjects: 6
Study 11453902 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5% + Erythromycin 2%
Number of subjects: 6
Study 9495223 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg single oral dose
Number of subjects: 12
Study 7520078 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound drainage
Number of subjects: 171
Study 7520078 — intervention group
Group type: COMPARATOR
Intervention: No wound drainage
Number of subjects: 171
Study 2497168 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (300 mg, sustained-release, Theo-Dur)
Number of subjects: 6
Study 2497168 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn sodium (10 mg)
Number of subjects: 6
Study 1092420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent positive-pressure ventilation (I.P.P.V.) of 10 mg of salbutamol
Number of subjects: 78
Study 1092420 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose (200 mug) from a pressurized canister
Number of subjects: 78
Study 447817 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (250 mg every 8 h over a period of 40 h)
Number of subjects: 13
Study 447817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31425700 — intervention group
Group type: EXPERIMENTAL
Intervention: 13 mg/day total MXans
Number of subjects: 59
Study 31425700 — intervention group
Group type: EXPERIMENTAL
Intervention: 27 mg/day total MXans
Number of subjects: 59
Study 31425700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 30136102 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg twice daily
Number of subjects: 21
Study 30136102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER 200 mg in the morning, 100 mg in the evening
Number of subjects: 21
Study 30136102 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of pregabalin 150 mg and tramadol ER 200 mg in the morning, and pregabalin 150 mg and tramadol ER 100 mg in the evening
Number of subjects: 21
Study 26728611 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (90 mg once daily for nine days)
Number of subjects: 100
Study 26728611 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (75 mg twice daily for nine days)
Number of subjects: 100
Study 25141536 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise with self-manual therapy
Number of subjects: 43
Study 25141536 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise without self-manual therapy
Number of subjects: 43
Study 22230651 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (3.2±2.3mg/day)
Number of subjects: 35
Study 22230651 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (9.2±4.9mg/day)
Number of subjects: 35
Study 20122041 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month education program for nursing staff
Number of subjects: 184
Study 20122041 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 184
Study 17644512 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-anginal drug therapy in addition to risk factor control (MED)
Number of subjects: 54
Study 17644512 — intervention group
Group type: COMPARATOR
Intervention: Risk factor control-only (RFC)
Number of subjects: 54
Study 17644512 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-anginal drug therapy (MED)
Number of subjects: 54
Study 16227030 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g amino acids (AA)/(kg.d) from birth onward
Number of subjects: 135
Study 16227030 — intervention group
Group type: COMPARATOR
Intervention: Glucose only during the first day with a stepwise increase in AA intake to 2.4 g AA/(kg.d) on day 3
Number of subjects: 135
Study 12058521 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 0
Study 12058521 — intervention group
Group type: COMPARATOR
Intervention: Standard individual intervention program
Number of subjects: 0
Study 10086669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride, 10 mg q.i.d. for 4 days
Number of subjects: 17
Study 10086669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 7648705 — intervention group
Group type: EXPERIMENTAL
Intervention: cA2, a chimaeric anti-TNF-α monoclonal antibody (MoAb)
Number of subjects: 2
Study 7648705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 2033450 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation plus MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone)
Number of subjects: 0
Study 2033450 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 0
Study 2033450 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation plus MOPP
Number of subjects: 0
Study 6453988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative condition
Number of subjects: 30
Study 6453988 — intervention group
Group type: COMPARATOR
Intervention: Competitive condition
Number of subjects: 30
Study 6453988 — intervention group
Group type: COMPARATOR
Intervention: Individualistic condition
Number of subjects: 30
Study 6453988 — intervention group
Group type: EXPERIMENTAL
Intervention: Handicapped students
Number of subjects: 30
Study 31955940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralong, 6.35-cm, 20-gauge ultrasonographically guided intravenous peripheral catheters
Number of subjects: 257
Study 31955940 — intervention group
Group type: COMPARATOR
Intervention: Standard long, 4.78-cm, 20-gauge ultrasonographically guided intravenous peripheral catheters
Number of subjects: 257
Study 31955940 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheters with greater than 2.75 cm inserted
Number of subjects: 257
Study 31955940 — intervention group
Group type: COMPARATOR
Intervention: Catheters with less than or equal to 2.75 cm inserted
Number of subjects: 257
Study 31955940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralong catheters
Number of subjects: 257
Study 31955940 — intervention group
Group type: COMPARATOR
Intervention: Standard long catheters
Number of subjects: 257
Study 30845037 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of prophylactic antibiotics (n = 4,523)
Number of subjects: 20682
Study 28110953 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) - PCI Choice
Number of subjects: 13
Study 26367803 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (self-regulatory strategies, role model support)
Number of subjects: 72
Study 26367803 — intervention group
Group type: COMPARATOR
Intervention: Stress management intervention (active control)
Number of subjects: 72
Study 26367803 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (with role model contact)
Number of subjects: 72
Study 26367803 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (without role model contact)
Number of subjects: 72
Study 26367803 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (exercise and stress management)
Number of subjects: 72
Study 24386952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab followed by pemetrexed at progression (Arm A)
Number of subjects: 55
Study 24386952 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cetuximab and pemetrexed (Arm B)
Number of subjects: 55
Study 24386952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab therapy
Number of subjects: 55
Study 24386952 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum proteomic classifier
Number of subjects: 55
Study 21692101 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Number of subjects: 60
Study 21692101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19782264 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 32
Study 19782264 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine retard
Number of subjects: 32
Study 18372700 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down bed rest (HDBR) for 60 days
Number of subjects: 24
Study 16314772 — intervention group
Group type: EXPERIMENTAL
Intervention: Douching intervention group
Number of subjects: 275
Study 16314772 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition (healthy eating and nutrition)
Number of subjects: 275
Study 11834660 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP trial of 5 cm H(2)O and FIO(2) of 40% (condition 1)
Number of subjects: 33
Study 11834660 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP trial of 5 cm H(2)O and FIO(2) of 21% (condition 2)
Number of subjects: 33
Study 11834660 — intervention group
Group type: COMPARATOR
Intervention: Spontaneously breathing room air trial without ventilatory support (condition 3)
Number of subjects: 33
Study 10192590 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 600
Study 10192590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 7578729 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug regimen 1 (3 doses of 3-5 mg/kg, on days 0, 3, and 10)
Number of subjects: 49
Study 7578729 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug regimen 2 (6 doses of 3-5 mg/kg, on days 0, 3, 6, 8, 10, and 13)
Number of subjects: 49
Study 7578729 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue therapy with L-AmB alone (3 mg/kg daily for 10 days)
Number of subjects: 49
Study 7578729 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 3 (4 doses of 4-5 mg/kg, on days 0, 2, 5, and 7)
Number of subjects: 49
Study 7578729 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal regimen of L-AmB
Number of subjects: 49
Study 2339368 — intervention group
Group type: EXPERIMENTAL
Intervention: F XIII concentrate administered within 6 hours after delivery
Number of subjects: 58
Study 2339368 — intervention group
Group type: COMPARATOR
Intervention: Non-treated group
Number of subjects: 58
Study 565418 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic amino acid infusions
Number of subjects: 17
Study 565418 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative keto-adaptation by a carbohydrate-free, oral protein diet
Number of subjects: 17
Study 565418 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative amino acid infusions only
Number of subjects: 17
Study 565418 — intervention group
Group type: COMPARATOR
Intervention: 5 percent dextrose infusions
Number of subjects: 17
Study 31984620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 33
Study 29315160 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (1200 IU)
Number of subjects: 400
Study 26252780 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 300
Study 26252780 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 300
Study 26252780 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 300
Study 25422826 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mm short implants
Number of subjects: 30
Study 25422826 — intervention group
Group type: COMPARATOR
Intervention: 10-mm long implants
Number of subjects: 30
Study 21912983 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment (2 Hz/32.4 mJ/5.9 J/cm(2))
Number of subjects: 28
Study 21912983 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser treatment (0.25 W/4.4 J/cm(2))
Number of subjects: 28
Study 21912983 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser treatment (0.50 W/8.9 J/cm(2))
Number of subjects: 28
Study 21912983 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28
Study 20523083 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based first-line chemotherapy
Number of subjects: 390
Study 20523083 — intervention group
Group type: COMPARATOR
Intervention: Non-platinum-based first-line chemotherapy
Number of subjects: 390
Study 20523083 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based second-line chemotherapy
Number of subjects: 390
Study 20523083 — intervention group
Group type: COMPARATOR
Intervention: Non-platinum-containing second-line chemotherapy
Number of subjects: 390
Study 20523083 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sequences (platinum-based first-line followed by non-platinum second-line and vice versa)
Number of subjects: 390
Study 18440702 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) ON
Number of subjects: 16
Study 18440702 — intervention group
Group type: COMPARATOR
Intervention: Spinal cord stimulation (SCS) OFF
Number of subjects: 16
Study 16188050 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin-resistant group
Number of subjects: 256
Study 16188050 — intervention group
Group type: COMPARATOR
Intervention: Aspirin-sensitive group
Number of subjects: 256
Study 11813818 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessment of emphysema using CT
Number of subjects: 0
Study 11813818 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative CT in the evaluation of patients with emphysema for surgery and drug therapy
Number of subjects: 0
Study 10435730 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiating leukapheresis based on rising WBC and platelet counts
Number of subjects: 190
Study 7554633 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 30 mg twice daily
Number of subjects: 1940
Study 7554633 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 1940
Study 7554633 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 10 mg once daily
Number of subjects: 1940
Study 7554633 — intervention group
Group type: COMPARATOR
Intervention: Low dose unfractionated heparin (5000 IU 3 times daily or 7500 IU twice daily)
Number of subjects: 1940
Study 7554633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1940
Study 7554633 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (30 mg twice daily, 40 mg once daily, 10 mg once daily)
Number of subjects: 1940
Study 7554633 — intervention group
Group type: COMPARATOR
Intervention: Low dose unfractionated heparin
Number of subjects: 1940
Study 1691377 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position after 1.5 hours rest
Number of subjects: 21
Study 1691377 — intervention group
Group type: COMPARATOR
Intervention: Sitting position after 1.5 hours rest
Number of subjects: 21
Study 1691377 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position after 2 hours rest
Number of subjects: 21
Study 1691377 — intervention group
Group type: COMPARATOR
Intervention: Sitting position after 2 hours rest
Number of subjects: 21
Study 373841 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephaloridine (3 doses, continued for 12 hours post-surgery)
Number of subjects: 297
Study 373841 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucloxacillin (2-week regimen, continued for 14 days post-surgery)
Number of subjects: 297
Study 31061432 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mtechnetium plus indocyanine green (ICG)
Number of subjects: 99
Study 31061432 — intervention group
Group type: COMPARATOR
Intervention: 99mtechnetium alone
Number of subjects: 99
Study 28639118 — intervention group
Group type: EXPERIMENTAL
Intervention: T0001 (10, 20, 35, 50, 65, or 75 mg)
Number of subjects: 56
Study 25938155 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal incision flap (Group A)
Number of subjects: 400
Study 25938155 — intervention group
Group type: COMPARATOR
Intervention: Angular incision flap (Group B)
Number of subjects: 400
Study 25938155 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 400
Study 23725215 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting beta-agonists
Number of subjects: 591
Study 21557649 — intervention group
Group type: EXPERIMENTAL
Intervention: aIAT congruent block (associating intentions with true sentences)
Number of subjects: 0
Study 21557649 — intervention group
Group type: COMPARATOR
Intervention: aIAT incongruent block (associating intentions with false sentences)
Number of subjects: 0
Study 21557649 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intentions with hopes
Number of subjects: 0
Study 19347033 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved systolic/diastolic BP (SBP/DBP) <130/75-79 mm Hg in patients with LVH
Number of subjects: 4553
Study 19347033 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved SBP/DBP <130/75-79 mm Hg in patients with DM or CKD
Number of subjects: 4553
Study 16863716 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised food frequency questionnaire (FFQ)
Number of subjects: 105
Study 16863716 — intervention group
Group type: COMPARATOR
Intervention: Fred Hutchinson FFQ
Number of subjects: 105
Study 12755836 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonist (300 mg nizatidine)
Number of subjects: 101
Study 12755836 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor (30 mg lansoprazole)
Number of subjects: 101
Study 12755836 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists (overall efficacy from 12 studies)
Number of subjects: 101
Study 12755836 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitors (overall efficacy from 12 studies)
Number of subjects: 101
Study 12755836 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonist (clarithromycin-containing regimens)
Number of subjects: 101
Study 12755836 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitors (non-clarithromycin-containing trials)
Number of subjects: 101
Study 11052441 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) 2 microg/kg/min for 6 hours after extubation
Number of subjects: 40
Study 11052441 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 40
Study 11052441 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (NTG and placebo)
Number of subjects: 40
Study 9071052 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine, dosage and duration not specified
Number of subjects: 0
Study 9071052 — intervention group
Group type: COMPARATOR
Intervention: Control group, not specified
Number of subjects: 0
Study 7529464 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (2 million units loading dose, 2 million units added to the CPB prime, and 500,000 units/hr maintenance infusion)
Number of subjects: 100
Study 7529464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 3164442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gammaglobulin (ivGG) infusion
Number of subjects: 20
Study 3164442 — intervention group
Group type: COMPARATOR
Intervention: Normal sera
Number of subjects: 20
Study 31705201 — intervention group
Group type: EXPERIMENTAL
Intervention: myMCT
Number of subjects: 80
Study 31705201 — intervention group
Group type: COMPARATOR
Intervention: waitlist control
Number of subjects: 80
Study 30262148 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian‐led Dietary Approaches to Stop Hypertension diet and physical activity coaching
Number of subjects: 281
Study 30262148 — intervention group
Group type: COMPARATOR
Intervention: Usual care (web-watcher)
Number of subjects: 281
Study 25793429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led breathing training program (8 sessions)
Number of subjects: 57
Study 25793429 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 57
Study 23672818 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine once daily (n = 32)
Number of subjects: 63
Study 23672818 — intervention group
Group type: EXPERIMENTAL
Intervention: IR-methylphenidate (n = 31)
Number of subjects: 63
Study 23672818 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 63
Study 20435261 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery (BSX)
Number of subjects: 0
Study 20435261 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty (BAP)
Number of subjects: 0
Study 18972727 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp-acupuncture plus exercise therapy
Number of subjects: 80
Study 18972727 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 80
Study 16359825 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min of moderate intensity cycle ergometry (n=18)
Number of subjects: 37